Obstructive sleep apnea (OSA) affects 22 million people in the U.S. and is linked to a higher risk of hypertension, heart attacks, stroke, diabetes and
...
VOXZOGO™ (vosoritide) earned U.S. Food and Drug Administration (FDA) approval on November 19, 2021, as the first therapeutic treatment for Achondroplasia. Pediatric orthopaedic surgeon Daniel
...
More than 250,000 people undergo a transurethral procedure each year in the U.S., and up
...
Continuous positive airway pressure (CPAP) is the treatment of choice for moderate-to-severe obstructive sleep apnea
...
(2/3/22) First delta, then omicron. The latest Covid variants have spread like wildfire across the
...
An international peer-reviewed medical journal examining global research trends in obstructive sleep apnea (OSA) found
...
(1/28/22) Researchers at the University of Missouri and the University of Minnesota have discovered how
...
A study from the University of Missouri School of Medicine and MU Health Care found
...